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The safety and efﬁcacy of 10/10 HLA antigen matched PBSC
HCT from unrelated donors (URD)s after nonmyeloablative con-
ditioning with ﬂudarabine (3 x 30 mg/m2) and 2 Gy TBI (FLU/2
Gy TBI) followed by cyclosporine (CSP) and MMF (both given
BID) for patients with hematologic malignancies ineligible for
conventional HCT was previously demonstrated (Maris, Blood
Vol 102, #6). Fifty-nine of the 71 pts who received PBSC grafts
had sustained engraftment. In that study, the half-life of mycophe-
nolate acid (active metabolite of MMF) was found to be 3 hours.
This suggested that TID dosing of MMF could improve postgraft-
ing immunosuppression and thereby increase engraftment rates.
Subsequently, a trial of dose escalated MMF (15 mg/kg TID) while
holding other HCT parameters constant was performed in 103 pts
given PBSC grafts from URDs after FLU/2 Gy TBI, CSP and
MMF, 15 mg/kg TID. The results in 69 patients with sufﬁcient
followup in this trial were compared to those in the previous 71 pts
given MMF BID. Median (med) age of TID MMF pts was 58
(range 17-70) years and that of BIDMMF pts was 54 (range 18-70)
years. The med follow-up of pts given MMF TID and BID was 9
and 25 months. The med neutrophil nadir was 100/l vs.740/l
(p  .01), but duration of absolute neutropenia was similar (8.5 vs
9 days, p  .43) for pts who received MMF TID and BID,
respectively. There were trends toward less graft rejection at 1 year
(7% vs.16%, p  .06) and higher peripheral blood donor CD3
chimerism at day 28 after HCT (90% vs 75%, p  .09) with TID
versus BID MMF. Other outcomes were not statistically different
between TID versus BID patient groups: The cumulative proba-
bilities (CP) of acute grades, II, III and IV GVHDwere 40%, 11%,
and 1% versus 41%, 10% and 3%, respectively. The CP of chronic
GVHD requiring therapy were 40% and 44%, respectively. The
Kaplan-Meier estimates at 1 year were 60% and 58% for overall
survival, and 44% and 44% for progression free survival, respec-
tively. The CP of relapse was 34% and 41%, respectively. The CP
of nonrelapse mortality (NRM) at day 100 and at 1 year were 9%
vs.11% and 22% vs.16%, respectively. We tentatively conclude
that MMF dosing for URD PBSC grafts after FLU/2 Gy TBI can
be safely increased from BID to TID without increasing toxicities,
NRM, or relapse rates. TID compared to BID dosing of MMF in
this setting may result in higher donor day 28 CD3 chimerism
values and sustained engraftment rates, while other outcomes were
comparable.
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ONCE DAILY INTRAVENOUS BUSULFAN AS PART OF A BUSULFAN/
CYCLOPHOSPHAMIDE CONDITIONING REGIMEN FOR ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
Mates, M., Michalska, H., Hasegawa, W., Kiss, T., Daly, A., Loach, D.,
Messner, H., Lipton, J. Princess Margaret Hospital, Allogeneic Bone
Marrow Transplant Program, University of Toronto, Toronto, ON,
Canada.
Objective: Busulfan (Bu) is frequently used as part of myeloab-
lative conditioning regimens prior to stem cell transplantation
(SCT), especially to avoid total body irradiation. Hepatic venooc-
clusive disease (HVOD) is a well-recognized dose-limiting toxicity
for oral Bu-preparative regimens. The purpose of this review was
to evaluate the toxicity, efﬁcacy, 100-day mortality, overall and
disease free survival in patients treated with single daily dose
intravenous (iv) Bu as part of a Bu/Cyclophosphamide (Cy) con-
ditioning regimen for allogeneic SCT. Patients and Methods: 29
consecutive patients undergoing allogeneic SCT received iv Bu as
part of their conditioning between March 2002 and August 2003.
Conditioning consisted of iv Bu (3.2mg/kg once daily x 4 doses)
followed by high dose Cy and allogeneic SCT. The donors were
HLA-matched siblings (n  23), 1 antigen mismatched related
donors (n  1) and matched unrelated donors (n  5). All patients
received graft versus host disease (GVHD) prophylaxis consisting
of Cyclosporine A and Methotrexate. Results: 28 patients en-
grafted with a median time for neutrophil recovery of 21 days
(12,29) and median time for platelets recovery of 18 days (10,49).
14 patients (48.3%) developed HVOD, 10 mild (34.5%), 2 mod-
erate (6.9%) and 2 severe HVOD (6.9%). Acute GVHD grade
II-IV occurred in 18 patients (64.3%). 3 patients (10.3%) died in
the ﬁrst 100 days after the transplant, with 1 death due to severe
HVOD (3.4%), 1 due to graft failure (3.4%) and 1 to other
transplant related toxicity (3.4%). After a median follow up of 8
months (1,16) chronic GVHD occurred in 12 out of 24 evaluable
patients (50%), 2 patients relapsed (6.9%), 1 patient is still in a
partial remission (3.4%) and a total of 7 patients died (24.1%). 22
patients (75.9%) were alive at their last follow up. Overall survival
at 6 months was 84.5%, and at 1 year 69.4%. 6-month disease-free
survival was 80.7% and at 1 year 67.3%. Conclusions: Condition-
ing regimens with single daily dose iv Bu allowed consistent en-
graftment from related and unrelated donors. Only one graft fail-
ure occurred in a patient undergoing a second allogeneic SCT
from a second matched related donor. 14 patients met criteria for
HVOD, but the majority of them were mild. Treatment related
mortality was limited. Overall survival and disease-free survival
rates are encouraging thus meriting further studies for deﬁning the
role of iv Bu as a preferred substitute for oral Bu.
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NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH PRE-TRANSPLANT IMMUNE DEPLETION RE-
SULTS IN RAPID FULL DONOR ENGRAFTMENT IN PEDIATRIC PATIENTS
WITH MALIGNANCY
Fry, T.J.1, Wayne, A.1, Fowler, D.2, Hakim, F.2, Love, C.1, Gress, R.2,
Bishop, M.2, Mackall, C.L.1 1. Pediatric Oncology Branch, NCI, NIH,
Bethesda, MD; 2. Experimental Transplantation and Immunology
Branch, NCI, NIH, Behtesda, MD.
Background: There is limited experience with non-myeloabla-
tive (NM) allogeneic hematopoietic stem cell transplantation
(alloSCT) in pediatric pts with cancer. In comparison to adults,
children and adolescents have less immune depletion and improved
reconstitution after chemotherapy, which might increase the risk
of mixed donor hematopoietic chimerism after NM alloSCT. Pro-
longed periods of mixed chimerism may increase the risk of relapse
in highly proliferative pediatric cancers. Methods: Twelve pedi-
atric pts (age 7-20, median 14.5 years) with high-risk malignancies
(Hodgkin’s disease, ALL, AML, CML, rhabdomyosarcoma, Ew-
ing’s sarcoma) were treated with a novel immunoablative regimen.
Fludarabine-based induction chemotherapy was administered for
disease control and host immune depletion (1 to 3 cycles). This was
followed by pre-transplant conditioning with cyclophosphamide
(1,200 mg/m2/day) and ﬂudarabine (30 mg/m2/day) x 4 days with
or without melphalan (100 mg/m2 x 1 dose). Unmodiﬁed, G-CSF
mobilized peripheral blood stem cells collected from HLA-
matched siblings were employed (CD34 doses of 6.9-19 x 106/kg).
Results: The regimen was associated with sequential lymphocyte
depletion, although to a lesser degree than in 18 adult pts (age
33-67, median 50 years) treated on a parallel trial (Table 1). IL7
levels were inversely correlated with CD4 counts (r2  0.20, p 
0.0006). Hematopoietic recovery was rapid in all pts. Complete
donor lymphoid chimerism (97% by VNTR-PCR on CD3
sorted peripheral blood) was achieved in 9 of 11 pts by post-
transplant day (D) 14, while 2 had mixed chimerism that im-
proved between D  14 to D  28 (70%3 85%, 85%3 95%
Table. Outcomes after Nonmyeloablative Conditioning Using URDs:
TID vs BID MMF
TID MMF
(n  69)
BID MMF
(n  71) P
1 year Graft Rejection 7% 16% .06
Day 28 T-cell Chimerism 90% 75% .09
100 day aGVHD Grades
II, III, IV 40%, 11%, 1% 41%, 10%, 3% .61
1-year CGVHD 40% 44% .35
1-year NRM 22% 16% .59
1-year Overall Survival 60% 58% .88
1-year Progression Free
Survival 44% 44% .89
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donor). Complete donor whole blood (WB) chimerism (unsorted
peripheral blood) was achieved in 7 of 11 pts by D  14, while 4
pts had mixed chimerism (30%, 69%, 88%, 95% donor). D  14
WB chimerism results were comparable to adult pts (13/18 com-
plete, 5 mixed-65%, 95%, 95%, 95%, 95% donor). There was a
trend towards a greater degree of mixed chimerism in younger pts
and those with less pre-transplant immune depletion. Conclu-
sions: Rapid, complete donor engraftment and chimerism can be
achieved in pediatric pts with cancer using a NM alloSCT regi-
men. Pre-transplant immune depletion appears to be somewhat
more difﬁcult to achieve compared to adult pts, particularly in
regard to CD8 T cells. Intensive immune depletion might be
required to consistently achieve rapid complete donor chimerism
in pediatric pts undergoing NM alloSCT.
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CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS RECEIVING EI-
THER ALEMTUZUMAB (CAMPATH 1-H) OR ANTITHYMOCYTE GLOBU-
LIN (ATG) AS GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS
PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (SCT)
Hunt, W.G.1,2, May, G.R.4, Krance, R.A.2,3, Heslop, H.E.2,3,4, Cathe-
rine, B.2,3, Kuehnle, I.2,3 1. Department of Pediatrics, Section of Pedi-
atric Infectious Diseases, Texas Children’s Hospital, Baylor College of
Medicine, Houston, TX; 2. Department of Pediatrics, Center for Cell and
Gene Therapy, Texas Children’s Hospital, Baylor College of Medicine,
Houston, TX; 3. Department of Pediatrics, Texas Children’s Cancer
Center, Texas Children’s Hospital, Baylor College of Medicine, Houston,
TX; 4. Center for Cell and Gene Therapy, The Methodist Hospital,
Houston, TX.
The potential of anti-leukocyte antibodies to decrease GVHD in
allogeneic SCT recipients has lead to inclusion of these antibodies
in chemotherapeutic regimens, some of which have been associated
with increased CMV infection in adults despite antiviral therapy.
To determine the effect of Campath 1-H or ATG on CMV
infection in nonmyeloablative or myeloablative regimens in pedi-
atric patients, we compared the retrospective incidence of CMV
infection and disease in 105 pediatric SCT recipients at Texas
Childrens Hospital over ﬁve years, from April 1998 throughMarch
2002. Eighty-four of the 105 patients had either seropositive donor
or recipient status, and all received either ganciclovir or foscarnet
prophylaxis. CMV antigenemia, polymerase chain reaction (PCR),
or buffy coat culture were monitored weekly for the ﬁrst 120 days
and subsequently as needed. CMV reactivation appeared similar
with Campath 1-H, 22/37 (59%), and ATG, 24/47 (51%, P  .5,
Power  80) and also was similar with the myeloablative and
nonmyeloablative groups, 39/70 (56%) and 7/14 (50%, P  .8),
respectively. There was a trend towards higher CMV reactivation
during the ﬁrst 120 days with Campath 1-H versus ATG, 21/37
(59%) in comparison to 17/47 (36%, P  .06), but this was not
statistically signiﬁcant. The incidence of CMV recurrence was
similar among all groups tested, as was the occurrence of GVHD.
Although there was a trend towards earlier CMV reactivation in
patients receiving Campath, disease was not more frequent, likely
associated with an increase in ganciclovir or change to foscarnet
upon positive CMV surveillance. One patient given Campath/
myeloablation and two receiving ATG/myeloablation had CMV
disease. A trend towards an increase in CMV reactivation during
the ﬁrst 100 days with Campath versus ATG likely reﬂects that
Campath depletes more cell lines than ATG, and this effect di-
minishes with engraftment. In summary, Campath 1-H was not
associated with a higher risk of CMV reactivation but was associ-
ated with earlier CMV reactivation without an increase in disease
compared to ATG. We are currently initiating a study evaluating
if adoptive immunotherapy with donor-derived CMV-speciﬁc cy-
totoxic T cells can reconstitute immunity to CMV and reduce the
rate of reactivation.
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MATCHED AND MISMATCHED UNRELATED CORD BLOOD (UCB) STEM
CELL TRANSPLANT (SCT) IN ADULTS: PRELIMINARY RESULTS OF AN
ONGOING PROSPECTIVE TRIAL
Chen, W., Stives, S., Visweshwar, N., Diaz, B., Yanbeiy, N., Ojha, R.,
Saad, M., Parumog, N., Farley, T., Nath, R. St. Joseph’s Regional
Medical Center, Paterson, NJ.
UCB has been commonly used as a source of allogeneic stem
cells in infants and children who lack a suitable HLA-matched
sibling donor. However, the success of UCB-SCT in adults is
limited by lower number of stem cells in cord blood which results
in delayed and reduced overall incidence of engraftment.
8 patients have been treated at SJRMC since August 2002. Di-
agnosis at transplant include MDS/AML (2), ALL (2), Burkitt
Lymphoma (1), HD (1), NHL (2). 6/8 patients had active disease,
1 had PhALL in 3rd remission, and 1 had testicular lymphoma
with history of bone marrow involvement in 2nd remission. 2 had
received prior radiation to the lungs/mediastinum. The median age
was 52 years (range 29-60). The median weight was 86 kg (range
66-104). 7 out of 8 patients were CMV seropositive.
All patients were uniformly conditioned with Thiotepa (10
mg/kg day–7), Busulfan (3.2 mg/kg day –6 to –4), Cyclophosph-
amide (60 mg/kg day –3 to –2), Anti-thymocyte globulin (20 mg/kg
day –4 and –2), and high dose Solu-medrol (500mg IV day –4 and
–2). GVHD prophylaxis consisted of Mycophenolate Mofetil (IV/
PO, day –1 to  56) and Tacrolimus (levels 5-20 ng/ml from day
–1). HLA match was 6/6 in one case, and 4/6 in seven cases based
on intermediate resolution matching on class I loci and high
resolution matching on class II loci. The median total nucleated
cell (TNC) dose based on pre-cryopreserved sample was 2.57
(range 1.88-3.96) x107/kg. Patients were infused a median of 1.99
(range 0.81-5.68) x 107 TNC/kg and 0.96 (range 0.70-2.50) x 105
CD34 cells/kg. All 8 patients engrafted. The median time to
ANC 200/l, 500/l, and 1000/l was day 22 (range 17-30), day
24 (range 20-35), and day 26 (range 23-38), respectively. The
median time to platelet count  20 x 109/l for 6 patients was day
64 (range 47 to156), and 50 x 109/l for 3 patients was day 170
(range 56-172). All 8 patients survived day 100. All 8 patients
achieved 100% donor chimerism on day 30. 7/8 had 100% donor
chimerism on day 100. 1 patient had 90% donor chimerism on day
100 and was found to have a leukemic relapse soon after. 5 patients
developed BK virus-induced hemorrhagic cystitis at the median
time of day 48 (range 25-60). 2 patients required surgical inter-
nention, one of which is currently asymptomatic.
Our preliminary results suggest that UCB-SCT is an appropriate
alternative for adult patients with high-risk hematological malig-
nancies who lack a suitable HLA-matched sibling donor.
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PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES FOLLOW-
ING MYELOABLATIVE ALLOGENIC BONE MARROW TRANSPLANTA-
TION-A TWELVE YEAR FOLLOW UP STUDY
Lamba, R., Abella, E., Dansey, R., Baynes, R., Klein, J., Karanes, C.
Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Signiﬁcance of various prognostic factors in myelodysplastic syn-
dromes was retrospectively explored in 82 patients who underwent
myeloablative allogenic stem cell transplantation between years
1988-1999 at Karmanos Cancer Institute, Detroit, Michigan. Fol-
low up ranged from 1 month to 12 years (median 4 years). Median
age was 45 years (range: 4-66 years). Preparative regimen was
busulfan, cytarabine and cyclophosphamide. Seventy-two patients
Table.
Pre Post Day 0
Pediatrics
CD4 206 108 (54%) 5.5 (99.0%)
CD8 361 193* (69%) 0.5 (100%)
Adults
CD4 253 70 (71%) 2.3 (99.7%)
CD8 217 47* (81%) 0.3 (99.9%)
Data represent median cell counts/mm3 (% depletion); *p  0.001; Pre: entry; Post: after
induction; Day 0: after conditioning.
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